Detalhe da pesquisa
1.
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
N Engl J Med
; 384(6): 497-511, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33264556
2.
Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response.
J Infect Dis
; 220(220 Suppl 4): S244-S252, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31671446
3.
Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines.
J Infect Dis
; 220(220 Suppl 4): S274-S278, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31671447
4.
Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
J Infect Dis
; 220(220 Suppl 4): S140-S147, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31671448
5.
Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine.
BMC Infect Dis
; 16(1): 639, 2016 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27814682
6.
Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.
Clin Infect Dis
; 61 Suppl 5: S531-9, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553685
7.
Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.
Clin Infect Dis
; 61 Suppl 5: S473-82, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553677
8.
Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
Clin Infect Dis
; 61 Suppl 5: S594-600, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553693
9.
Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
Clin Infect Dis
; 61 Suppl 5: S563-9, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553689
10.
Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.
Clin Infect Dis
; 61 Suppl 5: S416-21, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553669
11.
Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
Clin Infect Dis
; 61 Suppl 5: S434-41, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553672
12.
Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.
Clin Infect Dis
; 61 Suppl 5: S459-66, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553675
13.
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons.
Clin Infect Dis
; 61 Suppl 5: S501-6, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553681
14.
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
Clin Infect Dis
; 61 Suppl 5: S507-13, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553682
15.
Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
Clin Infect Dis
; 61 Suppl 5: S554-62, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553688
16.
Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.
Clin Infect Dis
; 61 Suppl 5: S586-93, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553692
17.
Public Health Impact After the Introduction of PsA-TT: The First 4 Years.
Clin Infect Dis
; 61 Suppl 5: S467-72, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553676
18.
Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.
Clin Infect Dis
; 61 Suppl 5: S422-7, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553670
19.
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Clin Infect Dis
; 61 Suppl 5: S514-20, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553683
20.
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Clin Infect Dis
; 61 Suppl 5: S521-30, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553684